SCHEMBL6872017

SCHEMBL6872017

CCCCCCC[C@@H](C)OC(=O)c1ccc(OC(=O)c2ccc(-c3ccc(C(=O)O[C@H](C)CCCCCCC)cc3)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
TSHR P16473 1/20 0.50
NPC1 O15118 3/20 0.49
LMNA P02545 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
NFKB1 P19838 3/20 0.49
NFKB2 Q00653 3/20 0.49
RELA Q04206 3/20 0.49
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
RARB P10826 3/20 0.47
MGLL Q99685 1/20 0.46
MAPT P10636 7/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
HPGD P15428 1/20 0.46
PRSS1 P07477 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6872611 1.00 ALDH1A1 (0.52) ALDH1A1TSHRNPC1LMNASMN1; SMN2
SCHEMBL6872703 0.99 TSHR (0.51) ALDH1A1TSHRNPC1LMNASMN1; SMN2
SCHEMBL10427474 0.95 ALDH1A1 (0.48) ALDH1A1TSHRNPC1LMNASMN1; SMN2
SCHEMBL6875651 0.95 TSHR (0.52) ALDH1A1TSHRNPC1LMNASMN1; SMN2
SCHEMBL8608966 0.94 NPC1 (0.59) ALDH1A1TSHRNPC1LMNASMN1; SMN2
SCHEMBL6697898 0.94 NPC1 (0.59) ALDH1A1TSHRNPC1LMNASMN1; SMN2
SCHEMBL6697893 0.94 NPC1 (0.59) ALDH1A1TSHRNPC1LMNASMN1; SMN2
SCHEMBL30201660 0.94 NPC1 (0.59) ALDH1A1TSHRNPC1LMNASMN1; SMN2
SCHEMBL7092890 0.94 NPC1 (0.59) ALDH1A1TSHRNPC1LMNASMN1; SMN2
SCHEMBL14207665 0.94 ALDH1A1 (0.47) ALDH1A1TSHRNPC1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6821581-B2 ESTER DERIVATIVES OF TEREPHTHALIC ACID ESTERS; HAVE A HELICAL TWISTING POWER OF AT LEAST 9; HELICAL PITCH INDUCED DECREASES IN LENGTH WITH AN INCREASE IN TEMPERATURE. MITSUBISHI GAS CHEMICAL CO., INC. (JP) 2004-11-23 US disclosed
US-20030124268-A1 Optically active compound and liquid crystal composition containing the compound MITSUBISHI GAS CHEMICAL CO., INC. 2003-07-03 US disclosed
EP-1270542-A1 Optically active compound and liquid crystal composition containing the compound MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2003-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030124268-A1 Optically active compound and liquid crystal composition containing the compound CRY1, CRY2, PNP ALDH1A1 4498/4885TSHR 4000/4885NPC1 366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.